CoAprovel 300/25 mg 14 tablets

CoAprovel 300/25 mg 14 tablets

Compound:

Each p / o tablet contains:

Irbesartan – 300 mg.

Hydrochlorothiazide 25 mg

Auxiliary components: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, red and yellow iron oxide, starch, opadrium Il pink, carnauba wax.

Properties:

CoAprovel is a combination of two active substances, irbesartan and hydrochlorothiazide. Irbesartan belongs to the group of angiotensin Il receptor antagonists. Angiotensin Il is a substance produced in the body that binds to receptors in blood vessels, causing them to contract, which leads to high blood pressure. Irbesartan prevents the binding of angiotensin-ll to these receptors, causing relaxation of blood vessels and lowering blood pressure. Hydrochlorothiazide is a thiazide diuretic that causes increased urine production and decreased blood pressure.

Indications:

Treatment of hypertension when monotherapy with irbesartan or hydrochlorothiazide does not provide adequate blood pressure control.

Mode of application:

Consult a physician before use. Recommended dose: 1 tablet daily. Inside, swallow the tablet with a sufficient amount of liquid, regardless of food intake. The daily dose should be taken at about the same time every day. The maximum effect of lowering blood pressure should be achieved 6-8 weeks after starting treatment. If you accidentally miss a daily dose, just take the next dose as usual. Do not take a double dose to make up for a forgotten dose.

Contraindications:

Children under the age of 18; hypersensitivity to irbesartan or to any of the other ingredients of the drug; pregnancy and lactation; severe liver or kidney problems, difficulty urinating; with the constant presence of high levels of calcium in the blood or low levels of potassium; diabetes; simultaneous reception with aliskiren.

Precautions:

When using the drug in patients with renal failure, periodic monitoring of the concentration of potassium and serum creatinine is recommended. In patients with psoriasis (including a history), the decision to use the drug should be made only after a careful assessment of the risk/ benefit ratio due to the possible exacerbation of the course of psoriasis. Patients with aortic or mitral stenosis or hypertrophic obstructive cardiomyopathy require caution. As with the use of other antihypertensive drugs, a significant decrease in blood pressure in patients with coronary artery disease and / or severe cerebral atherosclerosis can lead to the development of myocardial infarction or stroke. Treatment should be carried out under the control of blood pressure.

Hydrochlorothiazide can increase arterial hypotension, impair glucose tolerance, reduce the excretion of calcium in the urine and cause a transient, slight excess in the concentration of calcium in the blood plasma. Their use can distort the results of the study of the function of the parathyroid glands, therefore, before the study of the functions of the parathyroid glands, the thiazide diuretic should be canceled. An increase in the concentration cholesterol and triglycerides in the blood may occur. In some patients, the use of thiazide diuretics can lead to exacerbation of gout. Hydrochlorothiazide can cause the development of acute transient myopia and an acute attack of angle-closure glaucoma.

Side effects:

Dizziness, headache; tachycardia, excessive decrease in blood pressure, edema of the lower extremities; nausea, vomiting; diarrhea, dryness of the oral mucosa, abdominal pain; changes in the frequency of urination, myalgia, bone pain, weakness in the limbs; skin rash, itching; increased fatigue; weakness.

Storage:

Store at a temperature not exceeding 30C in its original packaging, protected from moisture and out of reach of children.

Packaging:

The package contains  p / o tablets in blisters; paper instructions.